Omeros Co. (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Omeros Co. (NASDAQ:OMER) have been given an average recommendation of “Moderate Buy” by the five research firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $22.50.

A number of analysts recently weighed in on the stock. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Tuesday. D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Tuesday.

Hedge Funds Weigh In On Omeros

Hedge funds have recently made changes to their positions in the business. Truvestments Capital LLC increased its holdings in Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP bought a new stake in Omeros in the fourth quarter worth $46,000. BNP Paribas Financial Markets increased its position in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 7,016 shares during the last quarter. Finally, Picton Mahoney Asset Management raised its holdings in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 4,404 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Trading Down 3.8 %

Shares of NASDAQ OMER opened at $7.91 on Wednesday. The company has a market cap of $458.38 million, a price-to-earnings ratio of -3.42 and a beta of 2.03. The stock’s 50 day simple moving average is $8.64 and its 200 day simple moving average is $7.61. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.